These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

93 related articles for article (PubMed ID: 6131248)

  • 21. Prostaglandin I2 and E1 and red cell deformability in raynaud's phenomenon and systemic sclerosis.
    Gaylarde PM
    Br Med J (Clin Res Ed); 1981 Dec; 283(6306):1608-9. PubMed ID: 6796187
    [No Abstract]   [Full Text] [Related]  

  • 22. The effect of infused prostacyclin in migraine and cluster headache.
    Peatfield RC; Gawel MJ; Rose FC
    Headache; 1981 Sep; 21(5):190-5. PubMed ID: 7026501
    [No Abstract]   [Full Text] [Related]  

  • 23. [New treatments for Raynaud's syndrome].
    Bellucci S; Kedra W; Ajzenberg N; Tobelem G; Caen J
    Nouv Rev Fr Hematol (1978); 1988; 30(1-2):103-7. PubMed ID: 3290833
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Preliminary experience with prostaglandins E1 and I2 in peripheral vascular disease.
    Pardy BJ; Lewis JD; Eastcott HH
    Surgery; 1980 Dec; 88(6):826-32. PubMed ID: 7003784
    [TBL] [Abstract][Full Text] [Related]  

  • 25. A method for administration of prolonged intravenous infusion of prostacyclin (PGI2) to unanesthetized rats.
    Weeks JR
    Prostaglandins; 1979 Apr; 17(4):495-9. PubMed ID: 379916
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Safety of coronary arterial prostacyclin infusion.
    Hall RJ; Dewar HA
    Lancet; 1981 Apr; 1(8226):949. PubMed ID: 6112358
    [No Abstract]   [Full Text] [Related]  

  • 27. Assessment of platelet function in patients with Raynaud's syndrome.
    Hutton RA; Mikhailidis DP; Bernstein RM; Jeremy JY; Hughes GR; Dandona P
    J Clin Pathol; 1984 Feb; 37(2):182-7. PubMed ID: 6229551
    [TBL] [Abstract][Full Text] [Related]  

  • 28. A randomised, double-blind study of cicaprost, an oral prostacyclin analogue, in the treatment of Raynaud's phenomenon secondary to systemic sclerosis.
    Lau CS; Belch JJ; Madhok R; Cappell H; Herrick A; Jayson M; Thompson JM
    Clin Exp Rheumatol; 1993; 11(1):35-40. PubMed ID: 8453795
    [TBL] [Abstract][Full Text] [Related]  

  • 29. Prolonged effect of CGRP in Raynaud's patients: a double-blind randomised comparison with prostacyclin.
    Shawket S; Dickerson C; Hazleman B; Brown MJ
    Br J Clin Pharmacol; 1991 Aug; 32(2):209-13. PubMed ID: 1931469
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Prostaglandin E-1 and peripheral vascular disease.
    Kyle V; Hazleman B
    Lancet; 1983 Jul; 2(8344):282. PubMed ID: 6135105
    [No Abstract]   [Full Text] [Related]  

  • 31. Epoprostenol (prostacyclin) and severe arterial disease. A double-blind trial.
    Belch JJ; McKay A; McArdle B; Leiberman P; Pollock JG; Lowe GD; Forbes CD; Prentice CR
    Lancet; 1983 Feb; 1(8320):315-7. PubMed ID: 6130330
    [TBL] [Abstract][Full Text] [Related]  

  • 32. Raynaud's syndrome.
    Cooke ED; Nicolaides AN
    BMJ; 1990 Mar; 300(6724):553-5. PubMed ID: 1691027
    [No Abstract]   [Full Text] [Related]  

  • 33. A cooling system for prostaglandin infusions.
    Krausz MM; Justice RE; Utsunomiya T; Hechtman HB
    Ann Biomed Eng; 1981; 9(3):257-62. PubMed ID: 7039429
    [No Abstract]   [Full Text] [Related]  

  • 34. The pharmacological effects of cicaprost, an oral prostacyclin analogue, in patients with Raynaud's syndrome secondary to systemic sclerosis--a preliminary study.
    Lau CS; McLaren M; Saniabadi A; Scott N; Belch JJ
    Clin Exp Rheumatol; 1991; 9(3):271-3. PubMed ID: 1879086
    [TBL] [Abstract][Full Text] [Related]  

  • 35. [Therapeutic use of prostacyclin in cardiovascular pathology].
    Martelli M; Nicolosi G
    Minerva Med; 1983 Nov; 74(44):2665-70. PubMed ID: 6419178
    [TBL] [Abstract][Full Text] [Related]  

  • 36. A double blind, randomised, multicentre comparison of two doses of intravenous iloprost in the treatment of Raynaud's phenomenon secondary to connective tissue diseases.
    Torley HI; Madhok R; Capell HA; Brouwer RM; Maddison PJ; Black CM; Englert H; Dormandy JA; Watson HR
    Ann Rheum Dis; 1991 Nov; 50(11):800-4. PubMed ID: 1722967
    [TBL] [Abstract][Full Text] [Related]  

  • 37. [Prostacyclin therapy of peripheral artery disease].
    Kusaba A
    Kokyu To Junkan; 1985 Jul; 33(7):871-6. PubMed ID: 3903902
    [No Abstract]   [Full Text] [Related]  

  • 38. The response of skin perfusion and of rheological and immunological variables to intravenous prostanoid administration in Raynaud's phenomenon secondary to collagenosis.
    Drinda S; Neumann T; Pöhlmann G; Vogelsang H; Stein G; Wolf G; Hein G
    Vasa; 2005 Nov; 34(4):243-9. PubMed ID: 16363279
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Raynaud's Syndrome: a neglected disease.
    Poredos P; Poredos P
    Int Angiol; 2016 Apr; 35(2):117-21. PubMed ID: 25673314
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Prevention of ischemic acute tubular necrosis with tris buffer or prostacyclin infusion.
    Isenberg GA; Hasday K; Oh J; Racelis D; Shapira Z; Schanzer H
    Mt Sinai J Med; 1981; 48(2):142-5. PubMed ID: 7012599
    [No Abstract]   [Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 5.